Abiopharma

🔍 Perry Griffin (Executive)

Company: Fermi Inc. (FRMI)

Report Date: 2026-03-30

Detailed Transactions and Holdings:

• Sold 9,000,000 shares of Common Stock, $0.001 par value at $5.0213 per share (Direct)
  Date: 2026-03-30 | Code: S | equity_swap_involved: false | shares_owned_after: 62,946,450.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,000,000 shares of Common Stock, $0.001 par value at $5.5384 per share (Direct)
  Date: 2026-03-31 | Code: S | equity_swap_involved: false | shares_owned_after: 60,946,450.00 | transaction_form_type: 4 | Footnotes: F4, F2

Footnotes:

• F1: The reported price is the weighted average sales price for the transactions reported on that line. Sales were made at prices between $4.9286-$5.346 per share. The Reporting Persons will provide to the Staff, the Issuer, or a security holder full information regarding the number of shares purchased or sold at each separate price upon request.
• F2: Reflects shares of common stock of Fermi Inc. (the "Issuer") directly held by Caddis Holdings, LP. Mr. Perry is a manager of Caddis Capital, LLC, the general partner of Caddis Holdings, LP, and may be deemed to beneficially own common stock of the Issuer held by Caddis Holdings, LP. Mr. Perry disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that Mr. Perry is the beneficial owner of such securities for purposes of Sections 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or for any other purpose. The Reporting Persons declare that neither the filing of this statement nor anything herein shall be construed as an admission that such persons are, for the purposes of Section 13(d) or 13(g) of the Exchange Act or any other purpose, a member of a group with respect to the Issuer or securities of the Issuer.
• F3: Caddis Holdings, LP was previously organized as Caddis Holdings, LLC and underwent a change in the form of the entity, without the transfer of any shares of the Issuer or any change in the beneficial ownership of such shares.
• F4: The reported price is the weighted average sales price for the transactions reported on that line. Sales were made at prices between $5.4003-$5.5494 per share. The Reporting Person will provide to the Staff, the Issuer, or a security holder full information regarding the number of shares purchased or sold at each separate price upon request.